GUD Knight Therapeutics

Notice of Knight Therapeutics' Second Quarter 2025 Results Conference Call

Notice of Knight Therapeutics' Second Quarter 2025 Results Conference Call

MONTREAL, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2025 financial results on Thursday, August 7, 2025 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date: Thursday, August 7, 2025

Time: 8:30 a.m. ET

Telephone: Toll Free: 1-888-699-1199 or International 1-416-945-7677

Webcast: or

This is a listen-only audio webcast. Media Player is required to listen to the broadcast.

Replay: An archived replay will be available for 30 days at .

________________________________________

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at or .

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2024, as filed on . Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

Investor Contact:  
Knight Therapeutics Inc.



  
Samira Sakhia Arvind Utchanah
President & Chief Executive Officer Chief Financial Officer
T: 514.484.4483 T. +598.2626.2344
F: 514.481.4116  
Email:  Email: 
Website:  Website: 
   


EN
01/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Knight Therapeutics

 PRESS RELEASE

Notice of Knight Therapeutics' Second Quarter 2025 Results Conference ...

Notice of Knight Therapeutics' Second Quarter 2025 Results Conference Call MONTREAL, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2025 financial results on Thursday, August 7, 2025 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Thursday, August 7, 2025Time: 8:30 a.m. ETTelephone: Toll Free: 1-888-699-1199 or International...

 PRESS RELEASE

Avis de conférence téléphonique de Thérapeutique Knight sur ses résult...

Avis de conférence téléphonique de Thérapeutique Knight sur ses résultats du deuxième trimestre 2025 MONTRÉAL, 01 août 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), publiera ses résultats financiers du deuxième trimestre 2025, ce jeudi 7 août 2025 avant l’ouverture du marché. À la suite de cette publication, Knight sera l’hôte d’une conférence téléphonique et d’une webémission. Knight invite cordialement toutes les parties intéressées à participer à cet appel. Date : Jeudi 7 août 2025 Heur...

 PRESS RELEASE

Knight Therapeutics Announces Regulatory Supplemental Submission of MI...

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with...

 PRESS RELEASE

Thérapeutique Knight annonce la soumission réglementaire supplémentair...

Thérapeutique Knight annonce la soumission réglementaire supplémentaire de MINJUVI® (tafasitamab) pour le traitement du lymphome folliculaire au Brésil MONTRÉAL, 31 juill. 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé aujourd’hui que sa filiale brésilienne, United Medical Ltda, a soumis une demande supplémentaire à ANVISA, agence brésilienne de réglementation de la santé, sollicitant l’approbation d’une indication supplémentaire pour MINJUVI® (tafasitamab) en association avec le ri...

 PRESS RELEASE

Knight Therapeutics Announces Filing of New Drug Submission for CREXON...

Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada MONTREAL, July 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for CREXONT® has been accepted for review by Health Canada. CREXONT® is a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease. The innovative design of CREXONT® allows for r...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch